Frozen plasma, buffy coat, FFPE blocks and slides
Research

Reference Medicine shares their new breast cancer research at ECP 2024

Sep 9, 2024

Medical Director, Zoran Gatalica, MD, presents new findings on TIL and HER2-low expression in relation to MammaPrint and BluePrint risk status.

Originally presented at the 36th European Congress of Pathology in Florence, Italy.

Download

Subscribe for updates

No spam — just the news you want: product launches, process improvements, and discounts on our already great pricing.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Media Contact

For more information or to schedule an interview, please contact:
Jen Ringler
ReadHealthy Communications
jringler@readhealthy.net

Share this post

More research
Research
Dec 11, 2024

Reference Medicine presents findings of MammaPrint® recurrence risk stratification in early-stage breast carcinomas at SABCS 2024

Read article
Research
Nov 23, 2024

Chris Diehnelt, Founder and CEO at Robust Diagnostics, presents peptide microarray research at AMP 2024

Read article
Research
Nov 22, 2024

Chris Diehnelt, Founder and CEO at Robust Diagnostics, presents Streck tube research at AMP 2024

Read article
See all
Process
Products
Pricing
Inventory

Subscribe to our newsletter

No spam — just the news you want: product launches, process improvements, and discounts on our already great pricing.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
 | 
© 2024 Reference Medicine. All rights reserved